Sarilumab for Relapse of Polymyalgia Rheumatica during Glucocorticoid Taper (SAPHYR Trial)

Dana McCormick, R.Ph., and Robert Spiera, M.D., delve into the SAPHYR trial, discussing sarilumab’s role in managing polymyalgia rheumatica relapse during glucocorticoid tapers.

Robert Spiera, M.D., discusses the SAPHYR trial, assessing sarilumab’s efficacy in treating refractory polymyalgia rheumatica.

Robert Spiera, M.D., reviews key patient characteristics from the study of sarilumab in refractory polymyalgia rheumatica.

Robert Spiera, M.D., explores sarilumab’s impact on polymyalgia rheumatica, emphasizing reduced steroid use and enhanced quality of life.

Robert Spiera, M.D., highlights the impact of sustained remission on polymyalgia rheumatica treatment, emphasizing improvements in quality of life and steroid-related effects.

Delving into the realm of refractory polymyalgia rheumatica, Robert Spiera, M.D., discusses the potential inclusion of sarilumab in revised guidelines. He addresses payer concerns regarding prior authorization while emphasizing the importance of ensuring appropriate patient access through evidence-based approaches.

Robert Spiera, M.D., discusses the criteria for determining the suitability of sarilumab in polymyalgia rheumatica patients, with a particular focus on indicators of steroid intolerance.

Robert Spiera, M.D., highlights the significance of the SAPHYR trial, presenting a nonsteroid option for patients with refractory polymyalgia rheumatica that addresses unmet needs, reduces long-term corticosteroid-related burdens and benefits healthcare providers, payers, and patients alike.